Committee bio
Dr Fatima Valdes Mora
Cancer Epigenetic Biology and Therapeutics,
Children’s Cancer Institute.
Sydney, NSW
Dr Fatima (Fa) Valdes Mora is Team Leader of the Cancer Epigenetic Biology and Therapeutics lab at the Children’s Cancer Institute (CCI) in Sydney.
Fa obtained her PhD in Molecular Biology, Biochemistry and Biomedicine from CSIC (Autonomous University of Madrid, Spain) in 2008. She then moved to Sydney to spend five years at the Cancer Epigenetics Lab, headed by Professor Susan Clark, at the Garvan Institute of Medical Research. Fa obtained a Group Leader position in the Histone Variants group at Garvan in 2014, and she joined CCI as Team Leader in 2020.
Fa is a mid-career researcher rising as an authority in cancer epigenetics research; she has played an integral role in discovering novel genome-wide roles of the acetylation of the histone variant H2A.Z, generating significant international interest.
Her passion for the development and implementation of novel technology has driven Fa to develop a strong multidisciplinary profile on cancer epigenetics, molecular and cellular biology, next-generation sequencing methodologies, single cell transcriptomics and epigenomics and bioinformatics interpretation of genome-wide data. Her current research focus is epigenetics in paediatric cancer and immuno-oncology.
Fatima is co-convenor of Epigenetics 2022, our next scientific meeting.
Early in 2008, Sue Clark brought a handful of epigenetics researchers from Australia together to form the Australian Epigenetics Alliance. The AEpiA has now grown to a membership of over 600, with members spanning not only Australasia, but the globe. In February 2021, our Victorian local organising committee hosted our eighth flagship Epigenetics conference, online for the first time. Our NSW team is now busy preparing for Epigenetics 2022, which will be held in September in Kingscliff, NSW.